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Abstract 
Purpose: To identify the causative mutation leading to autosomal dominant macular 
dystrophy, cone dystrophy and cone-rod dystrophy in a five-generation family and to explain 
the high intrafamilial phenotypic variation by identifying possible modifier genes.   
Methods: We investigated 15 family members by detailed ophthalmic and electrophysiologic 
phenotyping. Mutation screening was initially performed with microarrays that detect known 
mutations in genes associated with retinal degeneration. Furthermore, patients’ genomic 
DNA was analyzed by sequencing analysis of PRPH2, ABCA4 and ROM1. 
Results: Heterozygous mutations were identified in three genes and showed five different 
combinations within the studied family. All clearly affected family members carried the 
heterozygous PRPH2 mutation p.R172W. Patients with heterozygous sequence alterations 
only in ROM1 (p.R229H) or ABCA4 (p.V2050L) showed a mild ocular phenotype and were 
otherwise asymptomatic. The phenotypic severity of patients carrying the PRPH2 mutation 
increased with an additional mutation in ROM1. Patients carrying all three mutations were 
the most severely affected.  
Conclusions: Features of a PRPH2-associated phenotype might be modulated by additional 
mutations in other genes (in this family ABCA4 and/or ROM1) accounting for intrafamilial 
variability and resulting in a cumulative effect worsening the phenotype. We suggest that 
families showing a variable macular dystrophy phenotype caused by mutations in PRPH2 are 
tested for additional mutations in ABCA4 and ROM1 as they might alter the progression of 
the PRPH2 phenotype. This will influence genetic counseling as patients with additional 
mutations might be confronted with a faster progression of visual loss. 
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Introduction 
Mutations in the gene PRPH2 cause a wide phenotypic spectrum of autosomal dominant 
retinal dystrophies including retinitis pigmentosa,1-7 retinitis punctata albescens,8 cone-rod 
dystrophy,9-11 cone dystrophy,12, 13 adult vitelliform macular dystrophy,14-16 fundus 
flavimaculatus,17 pattern dystrophy,18, 19 and macular dystrophy.2, 20 
There are several explanations for a variable phenotype of a presumed monogenic disorder. 
The variation might be caused either by allelic heterogeneity, environmental factors or 
genetic modifiers.21 Modifiers are genes whose influence on the properties of the primary 
disease gene leads to phenotypic variability.22 
In mice, modifier loci in hereditary retinal disease phenotypes have been identified in the 
retinal degeneration mouse model rd3 and rd7 23, 24, in a murine retinoschisis 1 model 25, and 
in ocular retardation mice.26 Mouse models with modifying genetic backgrounds have also 
been developed for retinitis pigmentosa (RP).27, 28 Rpe65 has been suggested to modulate 
rhodopsin regeneration in a transgenic mouse model for autosomal dominant RP.29 In patient-
derived cell lines, modifier loci have been mapped in RP (Mendelian Inheritance in Man 
[MIM] #600138) caused by mutations in PRPF31.30  
The PRPH2 gene on chromosome 6 encodes 346 amino acids.31, 32 The gene product is a 
membrane-spanning glycoprotein located in the disc membranes of cone and rod 
photoreceptors. Peripherin is thought to act as a membrane stabilizer of the outer segment 
discs arrangement. This is further supported by the finding that knock out mice carrying a 
homozygous null mutation in perhipherin/rds fail to develop photoreceptor outer segments.33, 
34 Peripherin assembles into heterotetrameric complexes with the rod outer segment protein 1 
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(ROM1).35, 36 ROM1 is a disk rim integral membrane protein37, 38 and localizes to the rod and 
cone outer segments.35-37 ROM1 seems to be especially required for rod photoreceptor 
survival.39 
It has been described that the PRPH2 p.Leu185Pro allele and two protein-truncating ROM1 
mutations show a digenic inheritance, where only double-heterozygotes are affected by RP.6, 
7 A third ROM1 missense mutation has also been found to be associated with digenic RP.7 So 
far, no cases of RP have been reported that are caused by sequence changes in ROM1 alone. 
In contrast to ROM1, morphologically normal asymptomatic heterozygous ABCA4 mutation 
carriers showed functional impairment as revealed by reduced contrast sensitivity and 
reduced amplitudes in the multifocal ERG.40 The ABCA4 gene 41 codes for a retina specific 
membrane transporter protein. Similar as peripherin and ROM1, ABCA4 is situated in rod 
and cone outer segments.42, 43 It is suggested to play a major role in the recycling of all-trans 
retinal during the visual cycle.44, 45  
ABCA4 mutations have been found to cause autosomal recessive Stargardt disease (STGD1, 
MIM #248200),41, 46 fundus flavimaculatus which is considered an allelic disorder,47, 48 
autosomal recessive cone rod dystrophy49-54 and autosomal recessive RP.50, 55-58 An increased 
susceptibility for age-related macular degeneration due to ABCA4 sequence variations had 
also been postulated.59 However, this association was not confirmed in other studies.60-62 
Although PRPH2 mutations frequently are associated with variable phenotypes, the mutation 
p.R172W so far has shown an exceptional high intra- and interfamilial consistency for central 
retinal manifestations.13, 63-67 Only a single study described considerable phenotypic 
variability associated with this mutation.9 
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Here we describe a five-generation family with the p.R172W mutation in PRPH2 showing a 
remarkable intrafamilial variation of the ocular phenotype. Our data suggest that ABCA4 and 
ROM1 act as modifier genes of the PRPH2 p.R172W-associated phenotype. 
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Methods 
Patients and clinical investigation 
Informed consent was obtained prior to examination from all participants. All agreed to 
diagnostic services to identify disease-associated mutations. The study adhered to the tenets 
of the Declaration of Helsinki68 and was approved by the ethics committees of the University 
of Freiburg, Germany. 
Peripheral blood samples were drawn from 18 subjects. 15 members of this five-generation 
Caucasian German family with an autosomal dominant retinal dystrophy were included in the 
study according to Figure 1 (patient identification numbers 28586 (III-1), 28589 (III-2), 
28630 (III-4), 28628 (III-6), 28633 (III-7), 28590 (IV-1), 28588 (IV-2), 28585 (IV-3), 26593 
(IV-4), 28632 (IV-7), 28629 (IV-9), 28582 (V-1), 28587 (V-2), 28584 (V-3), 28583 (V-4)). 
Patients IV-5, V-5 and V-6 did not agree to scientific analysis of their DNA samples and 
were thus excluded from the scientific molecular genetic analysis.  
12 members (see Fig. 1) underwent a complete ophthalmic examination. They were queried 
about subjective complaints of loss of visual acuity, loss of visual fields, difficulties to see in 
dim/dark light conditions, photophobia, and color vision problems. In two subjects detailed 
clinical records of 13 years of preceding ophthalmic evaluation were available. Thorough 
medical histories were recorded. Member III-7 was excluded from the study as both eyes had 
preceding retinal detachment surgery. Member III-1 died shortly after genotyping and thus 
was not available for phenotyping. 
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Phenotyping included Goldmann and Octopus perimetry. Color vision was assessed with the 
Panel D 15 color vision test. For better comparison after ophthalmoscopy, fundus 
photographs were taken from the central and peripheral retina (Zeiss FF450 fundus camera, 
Carl Zeiss Jena GmbH, Jena, Germany). 
The severity of fundus changes was judged using a grading system of "minimal" – “mild" – 
"moderate" – "severe". Fundus autofluorescence (FAF) was recorded with a confocal 
scanning laser ophthalmoscope.69 Full-field electroretinograms (ERG, maximum flash 
intensity 1.8 cd·s/m2; Nicolet, Madison, USA), multifocal electroretinograms (mfERG; 
VERIS 4.8, Electro-Diagnostic Imaging, Redwood City, California, USA) and 
electrooculograms (EOG, Nicolet, Madison, USA) were analyzed using binocular stimulation 
according to the ISCEV (International Society for Clinical Electrophysiology of Vision) 
guidelines and standards.70-72 ERG results concentrate on the scotopic 1.8 b-wave, i.e. the 
maximal rod-cone response, and cone flicker amplitude as they showed the pathologies of the 
rod and cone system most clearly for the different family members.  
DNA preparation and mutation analysis 
Genomic DNA was isolated from blood samples of the 18 family members using the 
Chemagic Magnetic Separation Module I (Chemagen, Baesweiler, Germany) and underwent 
routine diagnostic testing of molecular genetic defects in genes associated with retinal 
degenerative diseases. The genomic DNA of index patient IV-4 (26593) was analyzed by 
commercially available genotyping microarrays detecting known sequence alterations that 
have been described in genes causing autosomal dominant retinitis pigmentosa or in the 
ABCA4 gene (AD RP and ABCA4 panel, Asper Biotech, Tartu, Estonia). These analyses 
included the following genes: ABCA4, CA4, CRX, FSCN2, IMPDH1, NRL, PNR, PRPF3, 
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PRPF31, PRPF8, RDS, RHO, ROM1, RP1, RP9 and TOPORS. Detected sequence alterations 
were verified by sequencing (ABI3100; Applied Biosystems, Rotkreuz, Switzerland). In 
addition, we sequenced the PRPH2 and ROM1 coding exons including flanking intronic 
sequences of IV-4 and IV-6. ABCA4 was screened in patient V-4 by sequencing. We further 
verified pathogenic sequence alterations of PRPH2, ROM1 and ABCA4 in all family 
members (Fig. 1, Fig. 2). PCR conditions using 50-100 ng of genomic DNA as a template 
and HotFire polymerase (Solis BioDyne, Tartu, Estonia) were as follows: after an initial 15 
minutes at 95°C, we performed a denaturing step at 95°C, followed by annealing at 55-63°C, 
1 minute incubation at 72°C for 35 cycles, and a final extension at 72°C for 10 minutes. PCR 
primers are available upon request. Ahead of sequencing, the quality of amplified DNA 
fragments was controlled by agarose gel electrophoresis. Sequence variations on DNA and 
protein level are described as recommended by the Human Genome Variation Society 
(HGVS, http://www.hgvs.org/). 
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Results 
Molecular genetic findings 
We analyzed 15 members of a Caucasian family as shown in Figure 1 using molecular 
genetic techniques to identify the causative mutation and/or additional sequence alterations. 
Index patient IV-4 was initially screened using genotyping microarrays for known mutations 
described in genes associated with autosomal dominant retinitis pigmentosa and macular 
dystrophy. The initial referral diagnosis was Stargardt disease (STGD1), which prompted us 
to additionally screen for ABCA4 mutations by genotyping microarrays. In both analyses 
heterozygous mutations were identified either in PRPH2 or ABCA4. The PRPH2 mutation 
locates to exon 1 and constitutes a C to T exchange at nucleotide position 514 (c.514C>T). 
This missense mutation is predicted to cause an amino acid substitution (p.Arg172Trp, 
p.R172W). The PRPH2 mutation cosegregates with the disease in all affected family 
members and thus is considered to be the causative mutation leading to macular dystrophy 
(V-1, V-2, V-3, V-4, IV-1, IV-7, IV-9, III-6), cone dystrophy (III-4), and cone rod dystrophy 
(IV-4, III-2).  
To verify whether ROM1 mutations occurred in the family described herein, we sequenced 
all coding and flanking intronic regions of ROM1 in patients IV-4 and IV-7. We detected 
several polymorphic variants (IV-4: rs35904570, rs1801144, rs1799959, rs4387351; IV-7: 
rs1799959, rs4387351) in addition to a sequence alteration in exon 2 (c.686G>A; 
p.Arg229His, p.R229H)73 which so far has been described as a rare, non-pathogenic variant. 
The occurrence of this rare sequence alteration was tested in all other individuals and was 
identified in 7 members (III-2, IV-1, V-1, IV-4, V-4, III-6, IV-9) as well as excluded in 5 
family members (III-4, IV-7, V-2, III-1, V-3).  
Poloschek et al.                                               Modifier                                                            11 
A second mutation was detected by genotyping microarrays affecting exon 45 of ABCA4 
(c.6148G>C). It is predicted to lead to an amino acid substitution (valine to leucine at 
position 2050 (p.V2050L). The mutation was analyzed in all family members. The presence 
of additional pathogenic sequence alterations in ABCA4 was excluded by sequencing the 
complete coding region including exon-flanking intronic parts in V-3. 
Figure 2 summarizes the five different genotypes found in the family. For phenotypic 
description we divided the family members into five corresponding groups based on 
genotype (Fig. 1). 
Clinical findings 
Family members are grouped according to Figure 2. A detailed description of the clinical and 
electrophysiologic examination results is shown in Table 1. After a thorough analysis of all 
clinical data we identified the following differences between the five genotypes. 
Group 1: Mutation of PRPH2 (p.R172W)   
The youngest member of this group V-2 (22 years old) shows perifoveloar drusen and 
corresponding spots of increased FAF (Fig. 3). Her mfERG amplitudes are within the lower 
normal limit without eccentricity dependence, i.e. responses have the same amplitude across 
the retina from the center outward to the periphery of the stimulated area. This is in contrast 
to the young members from group 2 (her brother V-1, 26 years) and 3 (V-4, 22 years). The 
same is found, to a lesser extent, by comparing the older generation members IV-7 (this 
group) and IV-1 (group 2) (Fig. 4A).  
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These family members (also including the oldest III-4 (75 years old)) have normal or only 
slightly reduced rod responses. Cone responses are only reduced in III-4 but not in the 
younger members (Fig. 5).  
Group 2: Mutation of PRPH2 and ROM1 (p.R172W, p.R229H) 
Member V-1 complained about a flickering light sensation at age 22 at which his sister V-2 
(group 1) was still asymptomatic. V-1's FAF is more severely affected than the FAF of V-2 
as it shows a speckled pattern with a surrounding ring of increased FAF measuring 2 optic 
disc diameters (ODD) (Fig. 3). In the mfERG V-1 shows a more pronounced central 
amplitude reduction relative to the peripheral rings compared to his sister V-2 (group 1) (Fig. 
4A). ERG rod responses are normal or only slightly reduced for young subject V-1 and 56-
year-old subject IV-1. However, in contrast to group 1, the oldest subject III-2 (84 years-old) 
shows a severe loss of rod function. Cone responses are similar to group 1 with a reduction 
only at older ages (Fig. 5). 
Group 3: Mutation of PRPH2, ROM1 and ABCA4 (p.R172W, p.R229H, p.V2050L) 
V-4 shows more advanced macular degeneration on fundoscopy and FAF as the same aged 
member V-2 (group 1). Even the four years older V-1 (group 2) has less macular 
degeneration on funduscopy than V-4. However, FAF is already markedly altered. V-4's 
mother IV-4 shows moderate to severe macular atrophy compared to her six years older 
brother IV-1 (group 2) who shows only mild RPE atrophy. Her FAF is also more severely 
altered as the affected speckled area extends beyond the arcades whereas her brother displays 
speckles that stay within the vascular arcades (Fig. 3).  
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MfERG amplitudes of both group members IV-4 and V-4 are more severely reduced than her 
approximately age-matched relatives IV-1 (group 2) and V-2 (group 1). IV-4 shows the most 
severe mfERG amplitude reduction of all family members (Fig. 4A).  
Interestingly, only subjects of group 3 complained of nyctalopia. This could be explained by 
the rod findings in the ERG: IV-4 shows the most severe reduction of rod b-waves. 
Moreover, there is a rapid decline of rod function over a period of 2 years. In contrast, her 
brother IV-1 (group 2) has stable rod function over a 13 years period (Fig. 5).  
Group 4: Mutation of ROM1 (p.R229H) 
Members of this group show only minor fundus changes, e.g. minor RPE granularity in the 
older member III-6 and her son IV-9. FAF is normal (Fig. 3). However, the central mfERG 
amplitudes of both members are lower than their peripheral amplitudes (Fig. 4A). Figure 4B 
shows the macular dysfunction in a more obvious way: the lower part shows normalized ring 
ratios. Each ring is displayed in relation to the sum of all normal ring values and is 
normalized to the largest value. In contrast to the raw ring amplitudes of Fig. 4A, this factors 
out the interindividual amplitude variability and thus is more sensitive for radially localized 
loss. It reveals mild but clear central macular dysfunction for both members. 
Scotopic and photopic ERGs are normal (Fig. 5).  
Group 5: Mutation of ABCA4 (p.V2050L) 
V-3 shows minimal perifoveolar RPE defects and a normal FAF (Fig. 3). However, the 
central amplitude of the mfERG is reduced below the normal limit in both eyes. The 
pathologic amplitude reduction is more pronounced than in group 4 (Fig. 4A). ERG rod and 
cone responses are normal (Fig. 5). 
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In conclusion, we observed that the increase in severity of the retinal degeneration phenotype 
caused by a PRPH2 mutation correlates with the occurrence of additional mutations in 
ABCA4 and ROM1. Although the ERG alone does not discriminate differences in disease 
severity at young ages (e.g. generation V), those patients carrying all three mutations seem to 
be more strongly effected than carriers of only one or two mutations. 
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Discussion 
 
We found high phenotypic variability within a family where the p.R172W mutation in 
PRPH2 cosegregates with the disease. We provide support for a model where features of a 
mutation-induced phenotype can be modulated by additional mutations in other genes 
accounting for the intrafamilial variability observed in this family. It seems that additional 
mutations in ABCA4 and ROM1 result in a cumulative age-dependent effect worsening the 
patient’s phenotype.  
In members who carry only the PRPH2 mutation p.R172W (group 1), cone function seems to 
be predominantly affected with stable rod function. This indicates that an isolated p.R172W 
mutation leads to a macular dystrophy phenotype. 
Known ROM1 sequence alterations comprise 8 polymorphisms and 9 rare variants including 
the p.R229H rare variant.7, 73-75 This variant was identified in two autosomal dominant 
retinitis pigmentosa patients from two different families. In one family the alteration did not 
segregate with the disease.  
However, in the family described herein, members III-6 and IV-9 (group 4) who carried only 
the ROM1 p.R229H alteration displayed minor RPE granularity and a mild yet distinct loss of 
macular function in the mfERG. Thus we suggest that the heterozygous change p.R229H 
causes a mild macular dysfunction. This effect could explain that member V-1 of group 2 
(PRPH2 p.R172W and ROM1 p.R229H mutations) was already symptomatic at the same age 
when his sister of group 1 (V-2) carrying only the PRPH2 p.R172W mutation still did not 
display any symptoms. He also showed more pronounced FAF alterations than his sister. 
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Additionally mfERGs of V-1 and IV-1 showed a distinct eccentricity dependence that was 
not observed in members of group 1. Since three affected family members (group 1) did not 
carry the p.R229H mutation in ROM1, the sequence alteration is unlikely to be associated 
with digenic inheritance of the different phenotypes in the family described herein.  
Our data suggest that the presence of an additional ROM1 p.R229H mutation worsens the 
PRPH2 macular dystrophy phenotype and that the former description as a non-pathogenic 
rare variant should be reassessed. 
In mice with a Rom1-null allele the maximal scotopic response was lowered by 50% in 
comparison to that of age-matched controls.39 It might thus be possible that the loss of rod 
function observed in the oldest subject of group 2 (III-2) is attributable to the heterozygous 
ROM1 p.R229H mutation, which is supported by the fact that the oldest subject of group 1 
(III-4) carrying only the PRPH2 mutation showed normal rod responses. Nevertheless, we 
cannot exclude that this effect is partially attributable to the age difference between the two 
subjects.  
Usually, ABCA4 mutations are inherited in an autosomal recessive manner. The ABCA4 
p.V2050L heterozygous carrier reported herein (group 5, V-3) showed centrally reduced 
mfERG amplitudes and additionally minor fundus abnormalities. This suggests that the 
p.V2050L mutation in the heterozygous state is capable to mildly reduce macular function 
without an additional mutation on the second allele. Indeed, heterozygous mutations in 
ABCA4 have been reported to cause electrophysiologically detectable dysfunction in 
individuals who had no obvious clinical signs: Maia-Lopes et al. described and clinically 
characterized a heterozygous ABCA4 p.V2050L carrier within a family with Stargardt 
disease.40 MfERG amplitudes were found to be smaller than normal yet higher than those of 
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Stargardt disease patients despite otherwise normal findings. This can be attributed to the 
commonly accepted hypothesis that the severity of the phenotype is inversely correlated with 
residual ABCA4 function76 although there is evidence that ABCA4 disease severity might be 
modified by other factors, too.77 
Flicker amplitudes of the older group 3 member IV-4 were reduced below the normal limit in 
the ERG and rod function declined rapidly over a period of two years. In contrast, normal 
flicker amplitudes and stable rod function as shown in a follow-up exam 13 years after the 
initial presentation was found in her brother (group 2, IV-1) not carrying ABCA4 p.V2050L. 
This might hint at an additional effect of p.V2050L on generalized cone function and an 
acceleration of loss of rod function if the genotype also contains ROM1 p.R229H and PRPH2 
p.R172W. In support of this idea, it has been reported previously that ABCA4 p.V2050L can 
be associated with a rod-cone pattern of functional loss as described in one patient suffering 
from RP carrying a heterozygous p.V2050L mutation. Thus, it was postulated that ABCA4 
mutations might contribute to the phenotypic variability of retinitis pigmentosa.78 
Furthermore, delayed dark adaptation was found in heterozygous Abca4 transgenic mice.79   
Loss of cone function with normal rod function has also previously been reported in 9 British 
families with the PRPH2 p.R172W mutation.63 Nakawaza et al. found only moderately 
reduced rod function in a Japanese family with the p.R172W mutation. 64 Rod function was 
reduced in a British family in which 2 of 6 affected members showed rod involvement in the 
ERG.13, 63 Downes et al. attributed the effect to an unidentified second mutation in a gene 
other than PRPH2.  
Michaelides et al. were the first to describe a high intrafamilial variability in a family with the 
PRPH2 p.R172W mutation and a cone-rod dystrophy pattern.9 However, other genes, esp. 
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ROM1, were not screened. Leroy et al. excluded ROM1 as a modifier gene in two families 
with PRPH2 mutations different from p.R172W for those with retinitis pigmentosa.80  
PRPH2 has been shown to cause digenic forms of retinitis pigmentosa by genetic interaction 
with ROM1. In some families, carriers of the PRPH2 mutation p.Leu172Pro were not 
affected unless they additionally carried a mutation in the unlinked ROM1 gene.3 Peripherin 
and ROM1 build tetrameric protein complexes, a finding that provides the molecular link to 
the digenic inheritance pattern.81, 82 One might consider the finding of digenic inheritance as 
an extreme example of phenotype modification by an independent gene. 
Another exceptional example has been published for the recessively inherited Bardet-Biedl 
syndrome (BBS). In BBS, the clinical variability ranges from mild to severe phenotypes. 
Additionally, the same combination of mutations can be associated with different 
combinations of phenotypes. It has been shown that this phenotypic variability can be 
explained by different genotypes within the 12 BBS-associated genes. Moreover, in a two 
generation pedigree the presence of the disease itself was dependent on the presence of three 
mutated alleles in the same patient: one individual carried two nonsense BBS2 mutations 
without having a phenotype, whereas his affected brother carried a third nonsense mutation in 
BBS6.83 This indicated that three mutations in two different BBS genes where required to 
cause the disease. The same group described BBS families where two mutated alleles were 
sufficient to cause the disease, but the phenotype of individuals was stronger when a third 
mutation in a different BBS gene was present in the same patient.84 Together, these findings 
show that genetic modifiers can potentiate the disease phenotype. Furthermore, it is likely 
that different mutations cause distinct variations in the patients’ phenotype.  
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It is well documented that the PRPH2 mutation p.R172W is associated with variable 
phenotypes such as cone dystrophy, cone-rod dystrophy and various types of macular 
dystrophies. In the case described herein, we detected different phenotypic expressions within 
one family where all patients carried the PRPH2 mutation p.R172W. The presence of a 
known mutation in the unlinked gene ABCA4 and a sequence variant in ROM1 correlated 
with a modified phenotype which showed a more pronounced macular dysfunction. This 
observation was confirmed by funduscopy, mfERG and FAF. There were also hints that 
ROM1 alters rod function and ABCA4 might have an effect on generalized rod and cone 
function in the presence of the ROM1 sequence variation. Of course these findings are based 
on one family only with correspondingly low numbers for each genotype and additional 
sequence alterations cannot be excluded completely. However, our data support a model 
where in addition to a disease causing mutation in PRPH2 modifying sequence alterations 
influence the disease expression. As to ROM1, we suggest that the p.R229H sequence 
change, that has been described as a non-pathogenic rare variant so far, should be considered 
a mild mutation. Since heterozygous sequence alterations in ABCA4 have been described to 
cause mild forms of macular degeneration, it is plausible that the combination of PRPH2 and 
ABCA4 mutations leads to an altered phenotype.  
We suggest testing those families that show a variable macular dystrophy phenotype caused 
by mutations in PRPH2 for additional mutations in ABCA4 and ROM1 as they might alter the 
progression of the PRPH2 phenotype. This will aid genetic counseling as patients with 
additional mutations might have to face a faster progression of visual loss.  
Taken together, our data support the idea that the phenotypic expression of patients with 
retinal degenerations is influenced by a specific genetic environment as sequence alterations 
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in several genes relevant for survival and maintenance of retinal cells might have cumulative 
effects on retinal cell function. 
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Figure 1: Pedigree and genotype of a five-generation family. Circles: females; squares: males; 
slashed symbols: deceased family members; symbols with horizontal bar: macular dystrophy; black 
symbols with horizontal and vertical bar: cone dystrophy; black symbols: affected by cone-rod 
dystrophy; black symbols with question mark: affected according to interview of family members 
without possibility of phenotyping; arrow: index patient. Genotype data are presented underneath the 
patient from whom DNA was available: upper genotype: PRPH2; middle genotype: ROM1; lower 
genotype: ABCA4. Colored boxes around affected individuals illustrate phenotype severity that 
increases with increasing saturation. Importantly, we only compare phenotype severity within the 
same generation (green: 3rd generation, red: 4th generation, blue: 5th generation) to exclude a possible 
age confounding effect. The increase in severity of the retinal degeneration phenotype (caused by a 
PRPH2 mutation) correlates with the occurrence of additional mutations in ABCA4 and ROM1. Patient 
III-1 deceased shortly after genotyping so that a clinical evaluation was not possible.  
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Figure 2. Five different heterozygous genotypes were found in the family. Family members with a 
similar genotype were grouped accordingly. Mutations in PRPH2 (group 1); mutations in PRPH2, 
ROM1 (group 2); mutations in PRPH2, ROM1, ABCA4 (group 3); mutations in ROM1 (group 4); 
mutations in ABCA4 (group 5). : Member III-1 died shortly after genotyping. Members IV-5, V-5 and 
V-6 decided to not participate in scientific DNA analysis and consequently are not listed. Patient III-7 
was excluded from the study due to bilateral retinal detachment surgery. 
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Figure 3. For each patient fundus photographs and corresponding FAF recordings of the right eye are 
shown. Due to high intraocular symmetry left eyes are not shown. Patient III-2 is not included in this 
figure due to dense cataracts in both eyes and corresponding poor quality of fundus photographs 
(FAF was not possible). Patient III-7 was not included in the study due to bilateral retinal detachment. 
For a detailed description please refer to the Results section. G1–5: groups 1–5. 
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Figure 4A. For each of the nine patients the top parts show the mfERG trace array of the right eye. 
Below the trace arrays are amplitudes averaged for each ring. Crosses: right eye; open circles: left 
eye; Lower and upper dotted lines: 5% resp. 95% normal confidence interval; solid line: normal 
median; the electrophysiologic categories are indicated top right of each trace array and subdivided 
as follows: N: constant amplitude throughout the stimulated area; Z1–4: amplitude reduction (low ratio 
center/periphery–high ratio center/periphery); Z5: additional to central reduction peripheral amplitudes 
pathologically reduced; G1–5: groups 1–5. Patients III-2 and III-4 showed a global amplitude 
reduction and are not displayed in this figure due to economy of space. 
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Figure 4B. Mild central macular dysfunction of group 4 (G4). Top parts show the mfERG trace array 
of the right eye of members III-6 and IV-9. Below the trace arrays there are normalized ring ratios: 
Each ring is displayed in relation to the sum of all normal ring values and normalized to the largest 
value. This analysis brings out localized loss across eccentricity. Both members show a mild but clear 
central macular dysfunction as central amplitudes are reduced below the 5th percentile (ring1 in 
member III-6, rings 1 and 2 in member IV-9). Crosses: right eye; open circles: left eye; lower and 
upper dotted lines: 5% resp. 95% normal confidence interval; solid line: normal median.  
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Figure 5. ERG results. For each family member the scotopic b-wave amplitude (upper graph, 
recorded with a flash of 1.8 cd·s/m2) and the 30 Hz flicker amplitude (lower graph) is displayed. Rod 
responses are normal in group 1, lowered with age in group 2, reduced early in group 3, and normal 
in groups 4 and 5. Cones responses are reduced with age in groups 1 and 2, early reduced in group 
3, and normal in groups 4 and 5. X: average amplitude of right and left eye. Solid lines: 5% resp. 95% 
normal confidence interval; dashed line: normal median.  
Table 1. Detailed phenotypic data of all examined family members sorted by groups. A: global amplitude reduction; arcades: temporal vascular 
arcades; CTA: corresponding to atrophy; EOG: electrooculogram; ERG: full-field electroretinogram; ex.: examination; FAF: fundus autofluorescence; 
GP: Goldmann perimetry; inf: inferior; MA: macular atrophy; mfERG: multifocal electroretinogram; n.a.: not analyzable due to artifact; N: normal; ND: 
not done; ND*: not done because patient refused the examination; NL: normal limit; NR: not recordable; NR: no records; ON: optic nerve; OP: 
Octopus perimetry; P1 – 2: amplitude (ERG) or Arden ratio (EOG, normal range 1,7 – 3,3) below the lower normal limit (increasing reduction); ODD: 
optic disc diameter; sup: superior; VA: visual acuity; VF: visual field; Z1–4: amplitude reduction across eccentricity (the smaller the Z-number the more 
central the amplitude reduction); Z5: additional to central reduction peripheral amplitudes pathologically reduced. All degrees indicate diameter unless 
otherwise indicated. 
 
Patient Group 
Genotype 
Age 
at ex. 
VA Age at onset 
of symptoms 
Visual field Color vision  
(Panel D 15) 
Fundus FAF ERG 
scotopic 1.8 
b-wave 
amplitude 
ERG 
30 Hz 
flicker 
amplitude 
mfERG EOG  
Arden 
ratio OD / OS 
V-2 1 
p.R172W 
22 1.25 / 1.25 Asymptomatic OP: OD nasal 
sup small sco-
toma, OS 
normal; GP: 
OD normal 
OD desaturated: 2 
unspecific defects 
OS desaturated: 1 
unspecific defect   
OU: ON drusen, 
perifoveolar 
drusen OD > OS 
OU: ON 
drusen, peri-
foveolar punc-
tual increase 
OD > OS 
P1 N N OD 
N 
 
OS 
n.a. 
IV-7 1 
p.R172W 
45 0.2 / 0.1 40 – VA loss 
35 – photophobia 
 
GP: OU 
central 
scotoma 40° 
(I/2) 
OD: mild protan, 
deutan and tritan 
defects, OS: 
unspecific defects 
OU: macular RPE 
granularity, OS: 
0.5 ODD 
temporal MA 
OU: speckled 
beyond ar-
cades; OS: re-
duced at lower 
arcade indica-
ting atrophy, 1 
ODD 
N N Z5 ND* 
III-4 1 
p.R172W 
75 0.05 / 0.07 42 – VA loss 
photophobia (onset 
unknown) 
 
GP: OU 
central 
scotoma 30° 
(I/3) 
OU: marked protan 
and deutan defects 
OU: severe MA, 
4 ODD 
OU: reduced 
CTA, 4 ODD, 
surrounding 
speckles 
N P2 A P1 
V-1 2 
p.R172W, 
p.R229H 
26 0.9 / 0.9 22 – flickering light 
sensation 
OP: OD 
normal OS 
paracentral 
defects 10° 
from center 
OU: normal OU: mild macular 
RPE clumping 
OU: speckled, 
2 ODD, 
surrounding 
increase, OD: 
reticular 
increase  
P1 P1 Z3 N 
  21  Asymptomatic NRe NRe NRe ND ND ND Z1 ND 
IV-1 
 
2 
p.R172W, 
56 0.8 / 0.7 50 – adaptation 
difficulties 
GP: OU 
paracentral 
OU: mild unspecific 
defects, OS: 1 tritan 
OU: mild RPE 
atrophy 
OU: speckled, 
3 ODD 
N P1 Z4 P1 
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p.R229H 32 – photophobia 
30 – flickering light 
sensation, relative 
paracentral scotoma 
 
scotoma from 
1 - 10° radius 
(I/2, I/3 inf, I/4 
sup) 
OP: as in GP 
defect OD: moderate 
temporal optic 
nerve atrophy 
  47 1.0 / 1.0 32 – photophobia 
30 – flickering light 
sensation, relative 
paracentral scotoma 
 
GP: OU stable ND OU: mild RPE 
irregularity 
ND ND ND Z3 ND 
  43 0.9 / 0.9 GP: OU 
paracentral 
scotoma from 
3 - 10° radius 
(I/2 inf, I/4 
sup) 
OU: moderate 
tetartan defects 
OU: minor RPE 
irregularity 
ND P2 N ND P1 
III-2 
 
2 
p.R172W, 
p.R229H 
84 0.05 / 0.02 56 – photophobia 
30 – VA loss 
 
GP stable OU: not possible OU: severe MA  OU: NR due 
to dense 
cataracts 
P2 P2 Z4 P2 
  71 0.02 / 0.03 GP: OU sup 
VF loss, OS 
inf.VF con-
striction to 70°  
OU: not possible OU: severe MA ND ND ND ND ND 
V-4 3 
p.R172W, 
p.V2050L, 
p.R229H 
22 1.0 / 1.2 22 – photophobia in 
bright light 
22 – mild nyctalopia  
GP: OU sup 
mild constric-
tion 
(I/3,I/2,I/1), 
OS paracentral 
scotoma 5° 
(I/1), OP: 
reduction 
central 20°  
OU: normal OU: mild - 
moderate MA 
OU: speckled, 
3 ODD, 
encircling 
increase 
P1 N Z3 N 
IV-4 3 
p.R172W, 
p.V2050L, 
p.R229H 
50 0.2 / 0.3 49 – nyctalopia 
40 – photophobia 
35 – VF defects 
13 – mild VA loss 
 
GP: OD 
paracentral 
scotoma (III/4) 
10°, sensitivity 
loss for I/1, 
I/2, OS central 
scotoma 40° 
(I/3) extending 
temporally  
OU: marked protan 
and deutan defects 
OU: moderate 
MA extending 
beyond arcades, 
temporally > 1 
ODD severe MA, 
midperipheral 
RPE clumping, 
moderate 
temporal ON 
atrophy 
OU: speckled 
beyond 
arcades, 
reduced CTA 
(mild 
progression) 
P3 P2 Z5 P1 
  48 0.2 / 0.5 40 – photophobia 
35 – VF defects 
13 – mild VA loss 
 
 
GP: OD 
central 
scotoma 35° 
(I/3) extending 
temporally, OS 
central 
scotoma 40° 
(I/3) 
OD: marked protan 
and deutan defects 
OS: marked protan, 
deutan and tritan 
defects 
OU: mild 
pericentral MA to 
arcades, mid-
peripheral RPE 
clumping, nasally 
1 ODD RPE 
atrophy, moderate 
temporal ON 
atrophy 
OU: speckled 
beyond 
arcades, 
reduced CTA  
P2 P2 Z5 ND 
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IV-9 4 
p.R229H 
36 1.25 / 1.25 Asymptomatic OP and GP: 
normal 
OS: unsaturated: 2 
unspecific defects 
OU: normal OU: normal N N Z1 N 
III-6 4 
p.R229H 
68 1.0 / 1.0 Asymptomatic OP and GP: 
normal 
OS: unsaturated: 1 
unspecific defect 
OU: mild 
arteriolar 
narrowing, 
arteriovenous 
nipping 
OU: normal N N Z2 N 
V-3 5 
p.V2050L 
24 1.25 / 1.25 Asymptomatic OP and GP: 
Normal  
OD desaturated: 1 
unspecific defect 
OU: minimal 
perifoveolar RPE 
irregularity 
OU: subtle 
perifoveolar 
increase 
N N Z2 N 
References 
1. Farrar GJ, Kenna P, Jordan SA, et al. A three-base-pair deletion in the peripherin-
RDS gene in one form of retinitis pigmentosa. Nature 1991;354:478-480. 
2. Wells J, Wroblewski J, Keen J, et al. Mutations in the human retinal degeneration 
slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. Nat 
Genet 1993;3:213-218. 
3. Kajiwara K, Hahn LB, Mukai S, Travis GH, Berson EL, Dryja TP. Mutations in 
the human retinal degeneration slow gene in autosomal dominant retinitis 
pigmentosa. Nature 1991;354:480-483. 
4. Gruning G, Millan JM, Meins M, et al. Mutations in the human peripherin/RDS 
gene associated with autosomal dominant retinitis pigmentosa. Hum Mutat 
1994;3:321-323. 
5. Sullivan LS, Bowne SJ, Birch DG, et al. Prevalence of disease-causing mutations 
in families with autosomal dominant retinitis pigmentosa: a screen of known 
genes in 200 families. Invest Ophthalmol Vis Sci 2006;47:3052-3064. 
6.  Kajiwara K, Berson EL, Dryja TP. Digenic retinitis pigmentosa due to mutations 
at the unlinked peripherin/RDS and ROM1 loci. Science 1994;264:1604-1608. 
7. Dryja TP, Hahn LB, Kajiwara K, Berson EL. Dominant and digenic mutations in 
the peripherin/RDS and ROM1 genes in retinitis pigmentosa. Invest Ophthalmol 
Vis Sci 1997;38:1972-1982. 
8. Kajiwara K, Sandberg MA, Berson EL, Dryja TP. A null mutation in the human 
peripherin/RDS gene in a family with autosomal dominant retinitis punctata 
albescens. Nat Genet 1993;3:208-212. 
9.  Michaelides M, Holder GE, Bradshaw K, Hunt DM, Moore AT. Cone-rod 
dystrophy, intrafamilial variability, and incomplete penetrance associated with 
the R172W mutation in the peripherin/RDS gene. Ophthalmology 
2005;112:1592-1598. 
10.  Nakazawa M, Kikawa E, Chida Y, Tamai M. Asn244His mutation of the 
peripherin/RDS gene causing autosomal dominant cone-rod degeneration. Hum 
Mol Genet 1994;3:1195-1196. 
11. Nakazawa M, Kikawa E, Chida Y, Wada Y, Shiono T, Tamai M. Autosomal 
dominant cone-rod dystrophy associated with mutations in codon 244 
(Asn244His) and codon 184 (Tyr184Ser) of the peripherin/RDS gene. Arch 
Ophthalmol 1996;114:72-78. 
12. Fishman GA, Stone EM, Alexander KR, Gilbert LD, Derlacki DJ, Butler NS. 
Serine-27-phenylalanine mutation within the peripherin/RDS gene in a family 
with cone dystrophy. Ophthalmology 1997;104:299-306. 
13. Wroblewski JJ, Wells JA, 3rd, Eckstein A, et al. Macular dystrophy associated 
with mutations at codon 172 in the human retinal degeneration slow gene. 
Ophthalmology 1994;101:12-22. 
14. Renner AB, Tillack H, Kraus H, et al. Morphology and functional characteristics 
in adult vitelliform macular dystrophy. Retina 2004;24:929-939. 
15. Felbor U, Schilling H, Weber BH. Adult vitelliform macular dystrophy is 
frequently associated with mutations in the peripherin/RDS gene. Hum Mutat 
1997;10:301-309. 
16. Zhuk SA, Edwards AO. Peripherin/RDS and VMD2 mutations in macular 
dystrophies with adult-onset vitelliform lesion. Mol Vis 2006;12:811-815. 
Poloschek et al.                                               Modifier                                                            31 
17. Apfelstedt-Sylla E, Theischen M, Ruther K, Wedemann H, Gal A, Zrenner E. 
Extensive intrafamilial and interfamilial phenotypic variation among patients 
with autosomal dominant retinal dystrophy and mutations in the human 
RDS/peripherin gene. Br J Ophthalmol 1995;79:28-34. 
18. Nichols BE, Drack AV, Vandenburgh K, Kimura AE, Sheffield VC, Stone EM. 
A 2 base pair deletion in the RDS gene associated with butterfly-shaped pigment 
dystrophy of the fovea. Hum Mol Genet 1993;2:601-603. 
19. Nichols BE, Sheffield VC, Vandenburgh K, Drack AV, Kimura AE, Stone EM. 
Butterfly-shaped pigment dystrophy of the fovea caused by a point mutation in 
codon 167 of the RDS gene. Nat Genet 1993;3:202-207. 
20. Travis GH, Hepler JE. A medley of retinal dystrophies. Nat Genet 1993;3:191-
192. 
21. Haider NB, Ikeda A, Naggert JK, Nishina PM. Genetic modifiers of vision and 
hearing. Hum Mol Genet 2002;11:1195-1206. 
22. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet 2001;2:165-174. 
23. Danciger M, Ogando D, Yang H, et al. Genetic modifiers of retinal degeneration 
in the rd3 mouse. Invest Ophthalmol Vis Sci 2008;49:2863-2869. 
24. Haider NB, Zhang W, Hurd R, et al. Mapping of genetic modifiers of Nr2e3 
rd7/rd7 that suppress retinal degeneration and restore blue cone cells to normal 
quantity. Mamm Genome 2008;19:145-154. 
25. Johnson BA, Aoyama N, Friedell NH, Ikeda S, Ikeda A. Genetic modification of 
the schisis phenotype in a mouse model of X-linked retinoschisis. Genetics 
2008;178:1785-1794. 
26. Wong G, Conger SB, Burmeister M. Mapping of genetic modifiers affecting the 
eye phenotype of ocular retardation (Chx10or-J) mice. Mamm Genome 
2006;17:518-525. 
27. Liu Q, Saveliev A, Pierce EA. The severity of retinal degeneration in Rp1h gene-
targeted mice is dependent on genetic background. Invest Ophthalmol Vis Sci 
2009;50:1566-1574. 
28. Humphries MM, Kiang S, McNally N, et al. Comparative structural and 
functional analysis of photoreceptor neurons of Rho-/- mice reveal increased 
survival on C57BL/6J in comparison to 129Sv genetic background. Vis Neurosci 
2001;18:437-443. 
29. Samardzija M, Wenzel A, Naash M, Reme CE, Grimm C. Rpe65 as a modifier 
gene for inherited retinal degeneration. Eur J Neurosci 2006;23:1028-1034. 
30. Rio Frio T, Civic N, Ransijn A, Beckmann JS, Rivolta C. Two trans-acting 
eQTLs modulate the penetrance of PRPF31 mutations. Hum Mol Genet 
2008;17:3154-3165. 
31. Travis GH, Christerson L, Danielson PE, et al. The human retinal degeneration 
slow (RDS) gene: chromosome assignment and structure of the mRNA. 
Genomics 1991;10:733-739. 
32. Travis GH, Sutcliffe JG, Bok D. The retinal degeneration slow (rds) gene product 
is a photoreceptor disc membrane-associated glycoprotein. Neuron 1991;6:61-70. 
33. Sanyal S, De Ruiter A, Hawkins RK. Development and degeneration of retina in 
rds mutant mice: light microscopy. J Comp Neurol 1980;194:193-207. 
34. Sanyal S, Jansen HG. Absence of receptor outer segments in the retina of rds 
mutant mice. Neurosci Lett 1981;21:23-26. 
35. Arikawa K, Molday LL, Molday RS, Williams DS. Localization of peripherin/rds 
in the disk membranes of cone and rod photoreceptors: relationship to disk 
Poloschek et al.                                               Modifier                                                            32 
membrane morphogenesis and retinal degeneration. J Cell Biol 1992;116:659-
667. 
36. Moritz OL, Molday RS. Molecular cloning, membrane topology, and localization 
of bovine rom-1 in rod and cone photoreceptor cells. Invest Ophthalmol Vis Sci 
1996;37:352-362. 
37. Bascom RA, Manara S, Collins L, Molday RS, Kalnins VI, McInnes RR. Cloning 
of the cDNA for a novel photoreceptor membrane protein (rom-1) identifies a 
disk rim protein family implicated in human retinopathies. Neuron 1992;8:1171-
1184. 
38. Goldberg AF, Moritz OL, Molday RS. Heterologous expression of photoreceptor 
peripherin/rds and Rom-1 in COS-1 cells: assembly, interactions, and localization 
of multisubunit complexes. Biochemistry 1995;34:14213-14219. 
39. Clarke G, Goldberg AF, Vidgen D, et al. Rom-1 is required for rod photoreceptor 
viability and the regulation of disk morphogenesis. Nat Genet 2000;25:67-73. 
40. Maia-Lopes S, Silva ED, Silva MF, Reis A, Faria P, Castelo-Branco M. Evidence 
of widespread retinal dysfunction in patients with stargardt disease and 
morphologically unaffected carrier relatives. Invest Ophthalmol Vis Sci 
2008;49:1191-1199. 
41. Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific ATP-binding 
transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. 
Nat Genet 1997;15:236-246. 
42. Sun H, Nathans J. Stargardt's ABCR is localized to the disc membrane of retinal 
rod outer segments. Nat Genet 1997;17:15-16. 
43. Molday LL, Rabin AR, Molday RS. ABCR expression in foveal cone 
photoreceptors and its role in Stargardt macular dystrophy. Nat Genet 
2000;25:257-258. 
44. Sun H, Nathans J. Mechanistic studies of ABCR, the ABC transporter in 
photoreceptor outer segments responsible for autosomal recessive Stargardt 
disease. J Bioenerg Biomembr 2001;33:523-530. 
45. Sullivan JM. Focus on Molecules: ABCA4 (ABCR) - An import-directed 
photoreceptor retinoid flipase. Exp Eye Res 2009. 
46. Maugeri A, van Driel MA, van de Pol DJ, et al. The 2588G-->C mutation in the 
ABCR gene is a mild frequent founder mutation in the Western European 
population and allows the classification of ABCR mutations in patients with 
Stargardt disease. Am J Hum Genet 1999;64:1024-1035. 
47. Rozet JM, Gerber S, Souied E, et al. Spectrum of ABCR gene mutations in 
autosomal recessive macular dystrophies. Eur J Hum Genet 1998;6:291-295. 
48. Gerth C, Andrassi-Darida M, Bock M, Preising MN, Weber BH, Lorenz B. 
Phenotypes of 16 Stargardt macular dystrophy/fundus flavimaculatus patients 
with known ABCA4 mutations and evaluation of genotype-phenotype 
correlation. Graefes Arch Clin Exp Ophthalmol 2002;240:628-638. 
49. Briggs CE, Rucinski D, Rosenfeld PJ, Hirose T, Berson EL, Dryja TP. Mutations 
in ABCR (ABCA4) in patients with Stargardt macular degeneration or cone-rod 
degeneration. Invest Ophthalmol Vis Sci 2001;42:2229-2236. 
50. Cremers FP, van de Pol DJ, van Driel M, et al. Autosomal recessive retinitis 
pigmentosa and cone-rod dystrophy caused by splice site mutations in the 
Stargardt's disease gene ABCR. Hum Mol Genet 1998;7:355-362. 
51. Fishman GA, Stone EM, Eliason DA, Taylor CM, Lindeman M, Derlacki DJ. 
ABCA4 gene sequence variations in patients with autosomal recessive cone-rod 
dystrophy. Arch Ophthalmol 2003;121:851-855. 
Poloschek et al.                                               Modifier                                                            33 
52. Valverde D, Riveiro-Alvarez R, Aguirre-Lamban J, et al. Spectrum of the 
ABCA4 gene mutations implicated in severe retinopathies in Spanish patients. 
Invest Ophthalmol Vis Sci 2007;48:985-990. 
53. Klevering BJ, Blankenagel A, Maugeri A, Cremers FP, Hoyng CB, 
Rohrschneider K. Phenotypic spectrum of autosomal recessive cone-rod 
dystrophies caused by mutations in the ABCA4 (ABCR) gene. Invest Ophthalmol 
Vis Sci 2002;43:1980-1985. 
54. Maugeri A, Klevering BJ, Rohrschneider K, et al. Mutations in the ABCA4 
(ABCR) gene are the major cause of autosomal recessive cone-rod dystrophy. Am 
J Hum Genet 2000;67:960-966. 
55. Martinez-Mir A, Paloma E, Allikmets R, et al. Retinitis pigmentosa caused by a 
homozygous mutation in the Stargardt disease gene ABCR. Nat Genet 
1998;18:11-12. 
56. Shroyer NF, Lewis RA, Yatsenko AN, Lupski JR. Null missense ABCR 
(ABCA4) mutations in a family with stargardt disease and retinitis pigmentosa. 
Invest Ophthalmol Vis Sci 2001;42:2757-2761. 
57. Fukui T, Yamamoto S, Nakano K, et al. ABCA4 gene mutations in Japanese 
patients with Stargardt disease and retinitis pigmentosa. Invest Ophthalmol Vis 
Sci 2002;43:2819-2824. 
58. Rudolph G, Kalpadakis P, Haritoglou C, Rivera A, Weber BH. [Mutations in the 
ABCA4 gene in a family with Stargardt's disease and retinitis pigmentosa 
(STGD1/RP19)]. Klin Monatsbl Augenheilkd 2002;219:590-596. 
59. Allikmets R, Shroyer NF, Singh N, et al. Mutation of the Stargardt disease gene 
(ABCR) in age-related macular degeneration. Science 1997;277:1805-1807. 
60. Souied EH, Ducroq D, Rozet JM, et al. ABCR gene analysis in familial exudative 
age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41:244-247. 
61. De La Paz MA, Guy VK, Abou-Donia S, et al. Analysis of the Stargardt disease 
gene (ABCR) in age-related macular degeneration. Ophthalmology 
1999;106:1531-1536. 
62. Webster AR, Heon E, Lotery AJ, et al. An analysis of allelic variation in the 
ABCA4 gene. Invest Ophthalmol Vis Sci 2001;42:1179-1189. 
63. Downes SM, Fitzke FW, Holder GE, et al. Clinical features of codon 172 RDS 
macular dystrophy: similar phenotype in 12 families. Arch Ophthalmol 
1999;117:1373-1383. 
64. Nakazawa M, Wada Y, Tamai M. Macular dystrophy associated with monogenic 
Arg172Trp mutation of the peripherin/RDS gene in a Japanese family. Retina 
1995;15:518-523. 
65. Piguet B, Heon E, Munier FL, et al. Full characterization of the maculopathy 
associated with an Arg-172-Trp mutation in the RDS/peripherin gene. 
Ophthalmic Genet 1996;17:175-186. 
66. Reig C, Serra A, Gean E, et al. A point mutation in the RDS-peripherin gene in a 
Spanish family with central areolar choroidal dystrophy. Ophthalmic Genet 
1995;16:39-44. 
67. Kohl S, Christ-Adler M, Apfelstedt-Sylla E, et al. RDS/peripherin gene 
mutations are frequent causes of central retinal dystrophies. J Med Genet 
1997;34:620-626. 
68. World Medical Association Declaration of Helsinki: ethical principles for 
medical research involving human subjects. Jama 2000;284:3043-3045. 
69. von Ruckmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence 
with a scanning laser ophthalmoscope. Br J Ophthalmol 1995;79:407-412. 
Poloschek et al.                                               Modifier                                                            34 
70. Marmor MF, Holder GE, Seeliger MW, Yamamoto S. Standard for clinical 
electroretinography (2004 update). Doc Ophthalmol 2004;108:107-114. 
71. Marmor MF, Hood DC, Keating D, Kondo M, Seeliger MW, Miyake Y. 
Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol 
2003;106:105-115. 
72. Brown M, Marmor M, Vaegan, Zrenner E, Brigell M, Bach M. ISCEV Standard 
for Clinical Electro-oculography (EOG) 2006. Doc Ophthalmol 2006;113:205-
212. 
73. Bascom RA, Liu L, Humphries P, Fishman GA, Murray JC, McInnes RR. 
Polymorphisms and rare sequence variants at the ROM1 locus. Hum Mol Genet 
1993;2:1975-1977. 
74.Bascom RA, Liu L, Heckenlively JR, Stone EM, McInnes RR. Mutation analysis 
of the ROM1 gene in retinitis pigmentosa. Hum Mol Genet 1995;4:1895-1902. 
75. Martinez-Mir A, Vilela C, Bayes M, et al. Putative association of a mutant 
ROM1 allele with retinitis pigmentosa. Hum Genet 1997;99:827-830. 
76. Shroyer NF, Lewis RA, Allikmets R, et al. The rod photoreceptor ATP-binding 
cassette transporter gene, ABCR, and retinal disease: from monogenic to 
multifactorial. Vision Res 1999;39:2537-2544. 
77. Cideciyan AV, Swider M, Aleman TS, et al. ABCA4 disease progression and a 
proposed strategy for gene therapy. Hum Mol Genet 2009;18:931-941. 
78. Klevering BJ, Yzer S, Rohrschneider K, et al. Microarray-based mutation 
analysis of the ABCA4 (ABCR) gene in autosomal recessive cone-rod dystrophy 
and retinitis pigmentosa. Eur J Hum Genet 2004;12:1024-1032. 
79. Mata NL, Tzekov RT, Liu X, Weng J, Birch DG, Travis GH. Delayed dark-
adaptation and lipofuscin accumulation in abcr+/- mice: implications for 
involvement of ABCR in age-related macular degeneration. Invest Ophthalmol 
Vis Sci 2001;42:1685-1690. 
80. Leroy BP, Kailasanathan A, De Laey JJ, Black GC, Manson FD. Intrafamilial 
phenotypic variability in families with RDS mutations: exclusion of ROM1 as a 
genetic modifier for those with retinitis pigmentosa. Br J Ophthalmol 
2007;91:89-93. 
81. Goldberg AF, Molday RS. Defective subunit assembly underlies a digenic form 
of retinitis pigmentosa linked to mutations in peripherin/rds and rom-1. Proc Natl 
Acad Sci U S A 1996;93:13726-13730. 
82. Goldberg AF, Molday RS. Subunit composition of the peripherin/rds-rom-1 disk 
rim complex from rod photoreceptors: hydrodynamic evidence for a tetrameric 
quaternary structure. Biochemistry 1996;35:6144-6149. 
83. Katsanis N, Ansley SJ, Badano JL, et al. Triallelic inheritance in Bardet-Biedl 
syndrome, a Mendelian recessive disorder. Science 2001;293:2256-2259. 
84. Badano JL, Kim JC, Hoskins BE, et al. Heterozygous mutations in BBS1, BBS2 
and BBS6 have a potential epistatic effect on Bardet-Biedl patients with two 
mutations at a second BBS locus. Hum Mol Genet 2003;12:1651-1659. 
 
 
